




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 213/50, 211/32	A1	(11) International Publication Number: WO 99/36405 (43) International Publication Date: 22 July 1999 (22.07.99)
<p>(21) International Application Number: PCT/JP99/00111</p> <p>(22) International Filing Date: 14 January 1999 (14.01.99)</p> <p>(30) Priority Data: 10/6908 16 January 1998 (16.01.98) JP</p> <p>(71) Applicant (for all designated States except US): EISAI CO., LTD. [JP/JP]; 6-10, Koishikawa 4-chome, Bunkyo-ku, Tokyo 112 (JP).</p> <p>(72) Inventor; and (75) Inventor/Applicant (for US only): IIMURA, Yoichi [JP/JP]; 4-5-87, Ninomiya, Tsukuba-shi, Ibaraki 305-0051 (JP).</p> <p>(74) Agents: FURUYA, Kaoru et al.; Nihonbashi TM Building, 1-8-11, Nihonbashi-Horidomecho, Chuo-ku, Tokyo 103-0012 (JP).</p>		<p>(81) Designated States: CA, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published With international search report.</p>

(54) Title: PROCESS FOR PRODUCTION OF DONEPEZIL DERIVATIVE

(57) Abstract

The present invention provides a novel industrially or economically preferable process for production of a hydrogen halogenide salt of a Donepezil derivative having an excellent pharmacological action as medicament, namely, reaction of 1-indanone derivative with carbonate ester to obtain 2-alkoxycarbonyl-1-indanone derivative, followed by reaction with halogenated (4-pyridyl)methyl or a salt thereof and decarboxylation successively to obtain 2-(4-pyridyl)methyl-1-indanone derivative, then reaction with halogenated benzyl to obtain quaternary ammonium salt, then reduction, and synthetic intermediate thereof. In the formulae step 1, step 2, step 3 and step 5 R¹ represents a hydrogen atom or lower alkoxy; n represents an integer of 1 to 4; R² represents lower alkyl group; and X represents a halogen atom.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

Description

Process for production of Donepezil derivative


Field of the invention

The present invention relates to a novel industrial process for production of medicaments disclosed in JP-A 64-79151(1989) (EP-296,560-A1, US-4,895,841), specifically, Donepezil derivative having an excellent pharmacological action as prophylactic or medicament for senile dementia, especially for Alzheimer disease, and synthetic intermediates thereof. More specifically, it relates to a process for production of 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylnpiperidine (free base) as a synthetic precursor of Donepezil Hydrochloride (chemical name; 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylnpiperidine hydrochloride) disclosed in Example 4 of the aforementioned specification.


Prior Arts

As it was disclosed in Example 3 and 4 of JP-A 64-79151(1989), indanone derivative was produced by reacting 5,6-dimethoxy-1-indanone with 1-benzyl-4-formylnpiperidine in the presence of strong base such as lithium diisopropylamide (Example 3), followed by reduction (Example 4) for example. According to this method, yield for Donepezil through Example

3 and 4 was 50.8% ($62\% \times 82\%$).




Additionally, it is disclosed in Example 2, 4 and 6 of JP-A 8-225527 (1996) (EP-711,756-A1, US-5,606,064) that reaction of 5,6-dimethoxy-1-indanone with pyridin-4-aldehyde afforded 5,6-dimethoxy-2-(pyridin-4-yl)methyleneindan-1-one (Example 2), followed by reaction with benzyl bromide afforded 1-benzyl-4-(5,6-dimethoxyindan-1-on-2-ylidene)pyridinium bromide (Example 4), then reduction in the presence of platinum oxide afforded Donepezil (Example 6). According to this method, yield for Donepezil through Example 2, 4 and 6 was 58.5% ($87\% \times 83\% \times 81\%$).




Moreover, it is disclosed in Preparation Example 1 to 3 and Example 1 to 6 of WO97/22584 that reaction of (pyridin-4-yl)carboxyaldehyde with malonic acid afforded 3-(pyridin-4-yl)-2-propenoic acid (Preparation 1), followed by reduction afforded 3-(piperidin-4-yl)-2-propionic acid (Preparation 2), followed by reaction with methyl chlorocarbonate afforded 3-[N-(methoxycarbonyl)piperidin-4-yl]propionic acid (Preparation 3), followed by reaction with oxalyl chloride afforded methyl 4-(2-chlorocarbonyl)ethylpiperidin-1-

carboxylate (Example 1), followed by reaction with 1,2-dimethoxybenzene in the presence of aluminum chloride afforded methyl 4-[3-(3,4-dimethoxyphenyl)-3-oxopropyl]piperidin-1-carboxylate (Example 2), followed by reaction with tetramethyldiaminomethane afforded methyl 4-[2-(3,4-dimethoxybenzoyl)allyl]piperidin-1-carboxylate (Example 3), followed by treatment with sulfuric acid afforded methyl 4-(5,6-dimethoxy-1-oxoindan-2-ylmethyl)piperidin-1-carboxylate (Example 4), followed by treatment with base afforded 5,6-dimethoxy-2-(piperidin-4-ylmethyl)indan-1-one (Example 5), then reaction with benzyl bromide afforded Donepezil (Example 6).

Yield of Example 1 was not disclosed in this specification though, even it is supposed as 100%, total yield through all the steps was 19.3% ($70\% \times 84\% \times 100\% \times 68\% \times 79\% \times 61\%$).





However, maximum total yield for Donepezil from the generally used starting material was 58.5% in JP-A 8-225527(1996), next was 50.8% in JP-A 64-79151(1989), and the lowest was 19.3% in WO97/22584. Therefore, it was not sufficient in either case as an industrial process.

Additionally, the maximum yield among all was the method of JP-A 8-225527 (1996), however, yield of reduction in the last step was not reproducible, it, therefore, is assumed that the yield is inferior to JP-A 64-79151 (1989) actually. (See Reference example described below.) Even the yield disclosed in this specification was correct, the total yield was not superior to Prior Arts (50.8%, a yeild throughout all the steps in JP-A 64-79151 (1989)), therefore, it did not show any superior effects.


Accordingly, there was no industrially or economically preferable process for Donepezil derivative having an excellent pharmacological action as prophylactic or medicament for senile dementia, especially for Alzheimer disease increasing the numbers of patients dramatically and having much social interest.

Summary of the invention


Regarding the foregoing problems, the present inventors have proceeded with extensive research. As a result, it has been found surprisingly that a reaction using a novel quaternary ammonium salt (I) affords 82.5% of total yield from a generally used material to Donepezil derivative, establishing the present invention.

Namely, the present invention provides an industrially preferable process for production of Donepezil and synthetic intermediates thereof.

The invention provides a process for producing a hydrogen halogenide salt of a Donepezil derivative (II) represented by the following formula;




(wherein R^1 represents, the same as or different from each other, a hydrogen atom or a lower alkoxy group; n represents an integer of 1 to 4; and X represents a halogen atom.), comprising the step of reducing a quaternary ammonium salt (I) represented by the following formula;



(Wherein R^1 , n and X have the same meaning as defined above).

The invention provides a process for producing a Donepezil derivative from the salt (II) according to a conventional neutralization and then a process for producing a pharmacologically acceptable salt of the Donepezil derivative according to a conventional reaction to form such a salt.

The invention provides a quaternary ammonium salt (I) represented by the following formula;




(Wherein R¹, n and X have the same meaning as defined in Claim 1.)

Details for the present invention is one of the following processes for Donepezil.

- (1) reduction of quaternary ammonium salt (I),
- (2) reaction of 2-(4-pyridyl)methyl-1-indanone derivative (III) with halogenated benzyl to obtain quaternary ammonium salt (I), then reduction of (I),
- (3) reaction of 2-alkoxycarbonyl-1-indanone derivative (IV) with halogenated (4-pyridyl)methyl (V) or a salt thereof and decarboxylation successively to obtain 2-(4-pyridyl)methyl-1-indanone derivative (III), then reaction of (III) with halogenated benzyl to obtain quaternary ammonium salt (I), then reduction of (I) or
- (4) reaction of 1-indanone derivative (VI) with carbonate ester (VII) to obtain 2-alkoxycarbonyl-1-indanone derivative (IV), followed by reaction of (IV) with halogenated (4-pyridyl)methyl (V) or a salt thereof and decarboxylation successively to obtain 2-(4-pyridyl)methyl-1-indanone derivative (III), then reaction of (III) with halogenated benzyl to obtain quaternary ammonium salt (I), then reduction of (I).


These processes are illustrated in the following chemical

reaction scheme.



(Wherein R^1 , R^2 , n and X have the same meaning as defined above.)

Quaternary ammonium salt (I) in the present invention is represented by the following formula.



Wherein R¹ represents, same as or different from each other, a hydrogen atom or a lower alkoxy group, n represents an integer of 1 to 4 and X represents a halogen atom.

Lower alkoxy group herein means a straight or branched lower alkyl group having 1 to 6 carbon atoms bonded with oxygen atom, for example, methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, i-butoxy, t-butoxy, pentyloxy or hexyloxy group. Among these, methoxy group, in particular 5,6- dimethoxy, is preferable on the basis of pharmacological effect or safety for Donepezil derivative as a final compound.

Halogen atom herein represents bromine atom, chlorine atom, iodine atom or fluorine atom, and among them, bromine atom, chlorine atom or iodine atom affords preferable results.

Concrete examples for the quaternary ammonium salt (I) are in the following, however the invention is not limited to these examples only.

- (1) 1-benzyl-4-(1-indanon-2-yl)methylpyridinium chloride,
- (2) 1-benzyl-4-[(4-methoxy-1-indanon)-2-yl]methylpyridinium chloride,
- (3) 1-benzyl-4-[(5-methoxy-1-indanon)-2-yl]methylpyridinium

chloride,

(4) 1-benzyl-4-[(6-methoxy-1-indanon)-2-yl]methylnpyridinium chloride,

(5) 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylnpyridinium chloride,

(6) 1-benzyl-4-[(5,7-dimethoxy-1-indanon)-2-yl]methylnpyridinium chloride,

(7) 1-benzyl-4-[(4,7-dimethoxy-1-indanon)-2-yl]methylnpyridinium chloride,

(8) 1-benzyl-4-[(4,5-dimethoxy-1-indanon)-2-yl]methylnpyridinium chloride,

(9) 1-benzyl-4-[(6,7-dimethoxy-1-indanon)-2-yl]methylnpyridinium chloride,

(10) 1-benzyl-4-[(5,6,7-trimethoxy-1-indanon)-2-yl]methylnpyridinium chloride,

(11) 1-benzyl-4-[(5,6-diethoxy-1-indanon)-2-yl]methylnpyridinium chloride,

(12) 1-benzyl-4-(1-indanon-2-yl)methylnpyridinium bromide,

(13) 1-benzyl-4-[(4-methoxy-1-indanon)-2-yl]methylnpyridinium bromide,

(14) 1-benzyl-4-[(5-methoxy-1-indanon)-2-yl]methylnpyridinium bromide,


(15) 1-benzyl-4-[(6-methoxy-1-indanon)-2-yl]methylnpyridinium bromide,

(16) 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylnpyridinium bromide,

- (17) 1-benzyl-4-[(5,7-dimethoxy-1-indanon)-2-yl]methyldipyrindinium bromide,
 (18) 1-benzyl-4-[(4,7-dimethoxy-1-indanon)-2-yl]methyldipyrindinium bromide,
 (19) 1-benzyl-4-[(4,5-dimethoxy-1-indanon)-2-yl]methyldipyrindinium bromide,
 (20) 1-benzyl-4-[(6,7-dimethoxy-1-indanon)-2-yl]methyldipyrindinium bromide,
 (21) 1-benzyl-4-[(5,6,7-trimethoxy-1-indanon)-2-yl]methyldipyrindinium bromide or
 (22) 1-benzyl-4-[(5,6-diethoxy-1-indanon)-2-yl]methyldipyrindinium bromide.

Quaternary ammonium salt (I) in the present invention is a novel compound and is useful as a key intermediate to obtain the Donepezil derivative (II) in high yield.

Further, Donepezil derivative hydrogen halogenide salt (II) in the present invention is represented by the following formula.



Wherein R^1 , n and X have the same meaning as defined above.

Concrete examples for the Donepezil derivative hydrogen halogenide salts (II) are the hydrogen halogenide salt of the

following, however the invention is not limited to these examples only.

(1) 1-benzyl-4-(1-indanon-2-yl)methylpiperidine,

(2) 1-benzyl-4-[(4-methoxy-1-indanon)-2-yl]methylpiperidine,

(3) 1-benzyl-4-[(5-methoxy-1-indanon)-2-yl]methylpiperidine,

(4) 1-benzyl-4-[(6-methoxy-1-indanon)-2-yl]methylpiperidine,

(5) 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine,

(6) 1-benzyl-4-[(5,7-dimethoxy-1-indanon)-2-yl]methylpiperidine,

(7) 1-benzyl-4-[(4,7-dimethoxy-1-indanon)-2-yl]methylpiperidine,

(8) 1-benzyl-4-[(4,5-dimethoxy-1-indanon)-2-yl]methylpiperidine,

(9) 1-benzyl-4-[(6,7-dimethoxy-1-indanon)-2-yl]methylpiperidine,


(10) 1-benzyl-4-[(5,6,7-trimethoxy-1-indanon)-2-yl]methylpiperidine or

(11) 1-benzyl-4-[(5,6-diethoxy-1-indanon)-2-yl]methylpiperidine.

When necessary, Donepezil derivative hydrogen halogenide salt (II) in the present invention can be converted to a optional pharmaceutically acceptable salt thereof by a usual manner

(salt exchange), e.g., neutralization with base followed by treatment with acid, or treatment with excess acid. Kind of the salt is not limited either, however, hydrochloride is preferable.

Further, 2-(4-pyridyl)methyl-1-indanone derivative (III) in the present invention is represented by the following formula.




Wherein R^1 and n have the same meaning as defined above.

Concrete examples for the 2-(4-pyridyl)methyl-1-indanone derivative (III) are in the following, however the invention is not limited to these examples only.

- (1) 2-(4-pyridyl)methyl-1-indanone,
- (2) 2-(4-pyridyl)methyl-4-methoxy-1-indanone,
- (3) 2-(4-pyridyl)methyl-5-methoxy-1-indanone,
- (4) 2-(4-pyridyl)methyl-6-methoxy-1-indanone,
- (5) 2-(4-pyridyl)methyl-5,6-dimethoxy-1-indanone,
- (6) 2-(4-pyridyl)methyl-5,7-dimethoxy-1-indanone,
- (7) 2-(4-pyridyl)methyl-4,7-dimethoxy-1-indanone,
- (8) 2-(4-pyridyl)methyl-4,5-dimethoxy-1-indanone,
- (9) 2-(4-pyridyl)methyl-6,7-dimethoxy-1-indanone,
- (10) 2-(4-pyridyl)methyl-5,6,7-trimethoxy-1-indanone or
- (11) 2-(4-pyridyl)methyl-5,6-diethoxy-1-indanone.

These are known compounds, and can be produced according to the procedure disclosed in J. Heterocyclic Chem., 2(4), 366-70 (1965). (total yield = 48.4% (55% \times 88%)) for example, however, can be produced in much higher yield according to the present invention (total yield = 82.5% (98% \times 85% \times 100% \times 99%)).

Further, 2-alkoxycarbonyl-1-indanone derivative (IV) in the present invention is represented by the following formula.



Wherein R^2 represents a lower alkyl group, R^1 and n have the same meaning as defined above.

Lower alkyl group herein means a straight or branched alkyl group having 1 to 6 carbon atoms, for example, methyl, ethyl, *n*-propyl, *i*-propyl, *n*-butyl, *i*-butyl, *t*-butyl, pentyl or hexyl group. Among these, methyl, ethyl or propyl group is preferable.


Concrete examples for the 2-alkoxycarbonyl-1-indanone derivative (IV) are in the following, however the invention is not limited to these examples only.

- (1) 2-methoxycarbonyl-1-indanone,
- (2) 2-methoxycarbonyl-4-methoxy-1-indanone,
- (3) 2-methoxycarbonyl-5-methoxy-1-indanone,
- (4) 2-methoxycarbonyl-6-methoxy-1-indanone,

- (5) 2-methoxycarbonyl-5,6-dimethoxy-1-indanone,
- (6) 2-methoxycarbonyl-5,7-dimethoxy-1-indanone,
- (7) 2-methoxycarbonyl-4,7-dimethoxy-1-indanone,
- (8) 2-methoxycarbonyl-4,5-dimethoxy-1-indanone,
- (9) 2-methoxycarbonyl-6,7-dimethoxy-1-indanone,
- (10) 2-methoxycarbonyl-5,6,7-trimethoxy-1-indanone,
- (11) 2-methoxycarbonyl-5,6-diethoxy-1-indanone,
- (12) 2-ethoxycarbonyl-1-indanone,
- (13) 2-ethoxycarbonyl-4-methoxy-1-indanone,
- (14) 2-ethoxycarbonyl-5-methoxy-1-indanone,
- (15) 2-ethoxycarbonyl-6-methoxy-1-indanone,
- (16) 2-ethoxycarbonyl-5,6-dimethoxy-1-indanone,
- (17) 2-ethoxycarbonyl-5,7-dimethoxy-1-indanone,
- (18) 2-ethoxycarbonyl-4,7-dimethoxy-1-indanone,
- (19) 2-ethoxycarbonyl-4,5-dimethoxy-1-indanone,
- (20) 2-ethoxycarbonyl-6,7-dimethoxy-1-indanone,
- (21) 2-ethoxycarbonyl-5,6,7-trimethoxy-1-indanone or
- (22) 2-ethoxycarbonyl-5,6-diethoxy-1-indanone.

These are known compounds also, and can be produced quantitatively according to the procedure disclosed in Example 9-A1 of EP-534,859 (yield=98%).

Further, halogenated (4-pyridyl)methyl derivative (V) in the present invention is represented by the following formula. (Wherein X represents a halogen atom.)




Concrete examples for the halogenated (4-pyridyl)methyl derivative (V) are in the following. They can be salt.

- (1) (4-pyridyl)methyl chloride,
- (2) (4-pyridyl)methyl bromide or
- (3) (4-pyridyl)methyl iodide.

They are known compounds, and are available as reagents or industrial bulk materials generally.

Further, 1-indanone derivative (VI) in the present invention is represented by the following formula. (Wherein R^1 and n have the same meaning as defined above.)



Concrete examples for the 1-indanone derivative (VI) are in the following.

- (1) 1-indanone,
- (2) 4-methoxy-1-indanone,
- (3) 5-methoxy-1-indanone,
- (4) 6-methoxy-1-indanone,
- (5) 5,6-dimethoxy-1-indanone,
- (6) 5,7-dimethoxy-1-indanone,
- (7) 4,7-dimethoxy-1-indanone,

- (8) 4,5-dimethoxy-1-indanone,
- (9) 6,7-dimethoxy-1-indanone,
- (10) 5,6,7-trimethoxy-1-indanone or
- (11) 5,6-diethoxy-1-indanone.

They are known compounds also, and are available as reagents or industrial bulk materials generally.

Finally, carbonate ester (VII) in the present invention is represented by the formula $(R^2O)_2CO$. (Wherein R^2 have the same meaning as defined above.)

Concrete examples for the carbonate ester (VII) are in the following.

- (1) dimethyl carbonate,
- (2) diethyl carbonate,
- (3) dipropyl carbonate or
- (4) methylethyl carbonate.

They are known compounds also, and are available as reagents or industrial bulk materials generally.

Detailed processes for the present invention are as follows. (See the foregoing chemical reaction formulae.)

(1) Step 1

Reaction of 1-indanone derivative (VI) with carbonate ester (VII) to obtain 2-alkoxycarbonyl-1-indanone derivative (IV) comprises this step according to the procedure of Example 9-A1 in EP-534,859, the procedure in Chem.Pharm.Bull.42(3),541-550(1994) or the procedure in Tetrahedron,30,507-512,1974. Among them, Example 9-A1 in

EP-534,859 affords the highest yield and producible quantitatively.

(2) Step 2

Reaction of 2-alkoxycarbonyl-1-indanone derivative (IV) with halogenated (4-pyridyl)methyl derivative (V) or a salt thereof to obtain 2-alkoxycarbonyl-2-(4-pyridyl)methyl-1-indanone derivative (VIII) comprises this step.

This step can be done in the presence of base according to a usual manner.

In the non-aqueous system, base is not limited though, for example, sodium hydride, sodium, sodium amide, lithium diisopropylamide (LDA), lithium hexamethyldisilazane (LHMDS), sodium methoxide, sodium ethoxide or potassium t-butoxide can be used. Solvent in this step is not limited either, for example, DMF, THF, DMSO, dioxane, HMPA, HMPT or mixed solvents can be used.

Moreover, this step can be done in aqueous system also in the presence of phase transfer catalyst and base. Phase transfer catalyst herein is not limited though, they are quaternary ammonium salt, quaternary phosphonium salt or sulfonium salt generally.

Concrete examples for the quaternary ammonium salt are tetramethylammonium iodide, tetraethylammonium iodide, tetrapropylammonium iodide, tetrabutylammonium iodide, tetrapentylammonium iodide, tetrahexylammonium iodide, tetraheptylammonium iodide, tetraoctylammonium iodide,

tetrahexadecylammonium iodide, tetraoctadecylammonium iodide, benzyltrimethylammonium bromide, benzyltriethylammonium bromide, benzyltributylammonium bromide, 1-methylpyridinium iodide, 1-hexadecylpyridinium iodide, 1,4-diethylpyridinium iodide, tetramethyl-2-butylammonium chloride, trimethylcyclopropylammonium chloride, tetrabutylammonium bromide, tetraoctylammonium bromide, t-butylethyldimethylammonium bromide, tetradecyltrimethylammonium bromide, hexadecyltrimethylammonium bromide or octadecyltrimethylammonium bromide.

Additionally, concrete examples for the quaternary phosphonium salt are tributylmethylphosphonium iodide, triethylmethylphosphonium iodide, methyltriphenoxyphosphonium iodide, butyltriphenylphosphonium iodide, tetrabutylphosphonium bromide, benzyltriphenylphosphonium bromide, hexadecyltrimethylphosphonium bromide, hexadecyltributylphosphonium bromide, hexadecyldimethylphosphonium bromide or tetraphenylphosphonium chloride.

Further, concrete examples for the sulfonium salt are dibutylmethylsulfonium iodide, trimethylsulfonium iodide or triethylsulfonium iodide.

These phase transfer catalysts are available as reagents or industrial bulk materials generally.

Finally, in the aqueous system, base is not limited either, concrete examples are sodium hydroxide, potassium hydroxide or barium hydroxide.

Solvent in this step is not limited either, for example, water, water/toluene, water/benzene, water/xylene, water/halogenated hydrocarbon in particular a chlorinated hydrocarbon such as methylene chloride, chloroform, carbontetrachloride, etc. or mixed solvents can be used.

(3) Step 3

Decarboxylation of 2-alkoxycarbonyl-2-(4-pyridyl)methyl-1-indanone derivative (VIII) to obtain 2-(4-pyridyl)methyl-1-indanone derivative (III) comprises this step.

This step can be done in the presence of base according to a usual decarboxylation manner. Base is not limited either in this step, for example, potassium hydroxide, sodium hydroxide or barium hydroxide can be used.

Solvent in this step is not limited either, for example, lower alcohol such as ethanol, methanol or propanol, THF, DMF, DMSO, dioxane or mixed solvents can be used.

As another procedure for this step, decarboxylation can be done according to the manner disclosed in Tetrahedron Lett., 957,1973., in water/DMSO in the presence of sodium chloride.

(4) Step 4

Reaction of 2-(4-pyridyl)methyl-1-indanone derivative (III) with halogenated benzyl to obtain quaternary ammonium

salt (I) comprises this step.

This step can be done according to a usual manner to prepare quaternary ammonium salt. Examples for the halogenated benzyl are benzyl bromide or benzyl chloride. As solvent, acetonitrile, THF, DMF, DMSO, dioxane, 1,2-dimethoxyethane, ether, lower alcohol, acetone, MEK (2-butanone), MIBK (methylisobutylketone), N-methylpyrrolidone or mixed solvents can be used.

(5) Step 5

Reduction of quaternary ammonium salt (I) to obtain the Donepezil derivative hydrogen halogenide salt (II) as the final compound in the present invention comprises this step. Reduction procedure is not limited either, it is done by catalytic reduction in the presence of catalyst usually.

Concrete examples for the catalyst are platinum compound such as platinum oxide, palladium compound such as palladium/carbon, nickel compound such as Raney nickel, ruthenium compound such as ruthenium oxide. As solvent, water, lower alcohol such as ethanol or methanol, THF, DMF, DMSO, dioxane, N-methylpyrrolidone, halogenated hydrocarbon in particular a chlorinated hydrocarbon such as methylene chloride, chloroform, carbontetrachloride, etc., acetone, MEK, MIBK, acetonitrile, ethyl acetate, benzene, toluene, xylene or mixed solvents can be used.

Reaction condition in this step is not limited either, it will complete within several hours at room temperature and


under atmosphere pressure.

Obtained Donepezil derivative hydrogen halogenide salt (II) can be lead to a free base or a pharmacologically acceptable salt thereof according to a usual manner.

Examples

The present invention will now be described in more detail with reference to the following examples. It is needless to say that the technical scope of the present invention is not limited to these examples.

Example 1; Synthesis of 5,6-dimethoxy-2-(4-pyridyl)methyl-1-indanone



2.00g (7.57mmol) of 5,6-dimethoxy-2-ethoxycarbonyl-1-indanone synthesized according to the Example 9-A1 of EP-534,859 was dissolved in 40ml of DMF (dimethylformamide), then 0.73g (18.3mmol) of a dispersion of 60% sodium hydride in oil was added under cooling in iced water bath, then stirring was kept for 30 minutes at room temperature. It was cooled in iced water bath again, 1.49g (18.3mmol) of 4-pyridiylmethyl chloride (4-picolyl chloride) was added hereinto, and stirring was kept for 30 minutes under the same condition. Further stirring was kept overnight at room temperature. Under cooling in iced water

bath, 200ml of water was added hereinto, followed by extraction with 200ml of ethyl acetate. The organic layer was washed with 200ml of saturated brine twice, and dried with MgSO_4 , then concentration under reduced pressure afforded 3.40g of dark brown oil.


This oil was dissolved in 50ml of ethanol, then 10ml of water and 1.99g (30.3mmol) of 85.5%-potassium hydroxide were added hereinto, and was heated under reflux for 30 minutes. The reaction mixture was cooled to room temperature, and was concentrated under reduced pressure, then 50ml of water was added. Filtration of the precipitated crystal and drying afforded 1.82g of the pale brown crystalline title compound. (Yield: 85% through 2 steps)

melting point: 192-193°C (literature: 190-191°C (J. Heterocyclic Chem., 2(4), 366-70, 1965.)).

$^1\text{H-NMR}$ (400MHz, CDCl_3) δ (ppm) 2.66-2.74 (2H, m), 2.96-3.04 (1H, m), 3.12 (1H, dd, $J=7.6\text{Hz}$, $J=16.8\text{Hz}$), 3.35 (1H, dd, $J=4.4\text{Hz}$, $J=14\text{Hz}$), 3.92 (3H, s), 3.95 (3H, s), 6.82 (1H, s), 7.18 (2H, d, $J=6\text{Hz}$), 7.20 (1H, s), 8.51 (2H, d, $J=6\text{Hz}$).

ESI-MS: $m/z=284$ ($\text{M}+\text{H}$) $^+$.

Example 2; Synthesis of 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpyridinium bromide




1.00g (3.53mmol) of 5,6-dimethoxy-2-(4-pyridyl)methyl-1-indanone was dissolved in 30ml of acetonitrile under reflux condition, 0.50ml (4.21mmol) of benzyl bromide was added hereinto. After keeping heating under reflux for 2.5 hours, reaction mixture was cooled to room temperature, followed by concentration under reduced pressure. 50ml of n-hexane was added to the residue. Filtration of the precipitated crystal and drying afforded 1.60g of the pale yellow crystalline title compound. (Yield: quantitatively) melting point: 173-177°C.

$^1\text{H-NMR}$ (400MHz, DMSO- d_6) δ (ppm) 2.70 (1H, dd, $J=3.6\text{Hz}$, $J=16.4\text{Hz}$), 3.01 (1H, dd, $J=9.2\text{Hz}$, $J=14\text{Hz}$), 3.12 (1H, dd, $J=7.6\text{Hz}$, $J=16.4\text{Hz}$), 3.16-3.24 (1H, m), 3.30-3.98 (1H, m), 3.77 (3H, s), 3.83 (3H, s), 5.81 (2H, s), 7.06 (1H, s), 7.07 (1H, s), 7.38-7.48 (3H, m), 7.50-7.56 (2H, m), 8.13 (2H, d, $J=6.4\text{Hz}$), 9.14 (2H, d, $J=6.4\text{Hz}$).

ESI-MS: $m/z=374$ (M-Br)+.

Example 3; Synthesis of 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine hydrochloride (Donepezil Hydrochloride)



1.00g (2.20mmol) of 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpyridinium bromide was dissolved in 15ml of methanol. Hydrogenation in the presence of 0.1g of platinum

oxide (IV) was done for 3 hours at room temperature under atmosphere pressure. After the catalyst was filtered off, filtrate was concentrated under reduced pressure, 30ml of saturated sodium carbonate aqueous solution was added hereinto, followed by extraction with 50ml of ethyl acetate thrice. After drying with MgSO_4 , concentration under reduced pressure afforded 0.83g of Donepezil free base. (Yield: 99%)

$^1\text{H-NMR}$ (400MHz, CDCl_3) δ (ppm) 1.27-1.42 (3H, m), 1.42-1.55 (1H, m), 1.63-1.77 (2H, m), 1.87-2.03 (3H, m), 2.66-2.74 (2H, m), 2.86-2.94 (2H, m), 3.23 (1H, dd, $J=8\text{Hz}$, $J=17.6\text{Hz}$), 3.50 (2H, s), 3.90 (3H, s), 3.96 (3H, s), 6.85 (1H, s), 7.17 (1H, s), 7.22-7.33 (5H, m).

This was lead to hydrochloride according to a usual manner, and recrystallizaion from ethanol/isopropylether afforded 0.83g of the white crystalline title compound. (Yield: 91% through 2 steps)

melting point: 211-212°C (Decomposition) (literature: 211-212°C (Decomposition), (Example 4 of JP-A 64-79151 (1989))).

$^1\text{H-NMR}$ (400MHz, CDCl_3) δ (ppm) 1.48-1.58 (1H, m), 1.76-1.90 (2H, m), 1.90-2.02 (1H, m), 2.02-2.20 (3H, m), 2.60-2.76 (4H, m), 3.29 (1H, dd, $J=7.6\text{Hz}$, $J=17.2\text{Hz}$), 3.41-3.54 (2H, m), 3.90 (3H, s), 3.96 (3H, s), 4.12-4.22 (2H, m), 6.85 (1H, s), 7.12 (1H, s), 7.42-7.48 (3H, m), 7.64 (2H, br-s), 12.25-12.45 (1H, m).

ESI-MS: $m/z=380$ ($M+H$) $^+$.


Reference example 1; Synthesis of Donepezil (free base)

(Reproduction experiment result of the Example 6 in JP-A 8-225,527 (1996))


50ml of methanol and 1g of platinum oxide (IV) were added to 10.0g (22.1mmol) of 5,6-dimethoxy-2-(4-pyridyl)methyleneindan-1-one synthesized according to the Example 4 in JP-A 8-225,527(1996). Hydrogenation was done for 24 hours at room temperature under atmosphere pressure. After the catalyst was filtered off, filtrate was concentrated under reduced pressure, 200ml of 5%-sodium carbonate aqueous solution was added hereinto, followed by extraction with 150ml and 100ml twice of methylene chloride. After drying with MgSO_4 , concentration under reduced pressure afforded 9.1g of black oil. TLC (methanol/methylene chloride) analysis of this black oil showed many by-product spots. Purification of this oil by (NH)silicagelcolumnchromatography (n-hexane/ethyl acetate) afforded 3.2g of the white crystalline title compound. (Yield: 38%, literature: 81%, (Example 6 in JP-A 8-225,527(1996)))

Claims

1. A process for producing a hydrogen halogenide salt of a Donepezil derivative (II) represented by the following formula;




(wherein R^1 represents, the same as or different from each other, a hydrogen atom or a lower alkoxy group; n represents an integer of 1 to 4; and X represents a halogen atom.), comprising the step of reducing a quaternary ammonium salt (I) represented by the following formula;




(Wherein R^1 , n and X have the same meaning as defined above).

2. The process as claimed in Claim 1, in which the quaternary ammonium salt (I) is produced by reacting 2-(4-pyridyl)methyl-1-indanone derivative (III) represented by the following formula;




(Wherein R^1 and n have the same meaning as defined above.)
with a halogenated benzyl.

3. The process as claimed in Claim 2, in which 2-(4-pyridyl)methyl-1-indanone derivative (III) is produced by reacting 2-alkoxycarbonyl-1-indanone derivative (IV) represented by the following formula;



(Wherein R^2 represents a lower alkyl group, R^1 and n have the same meaning as defined above.)


with a halogenated (4-pyridyl)methyl (V) represented by the following formula or a salt thereof;



(Wherein X represents a halogen atom.)

and decarboxylating the reaction product.

4. The process as claimed in Claim 3, in which a 2-alkoxycarbonyl-1-indanone derivative (IV) is produced by reacting a 1-indanone derivative (VI) represented by the following formula;



(Wherein R^1 and n have the same meaning as defined above.)

with carbonate ester (VII) represented by $(R^2O)_2CO$;

(Wherein R^2 has the same meaning as defined above.).

5. The process as claimed in Claim 1, in which the reduction is catalytic reduction in the presence of platinum oxide, palladium/carbon, Raney nickel or ruthenium oxide.


6. The process as claimed in Claim 1, in which the halogen atom for X of the quaternary ammonium salt (I) is bromine atom, chlorine atom or iodine atom.

7. The process as claimed in Claim 3, in which the halogenated (4-pyridyl)methyl (V) is (4-pyridyl)methyl chloride, (4-pyridyl)methyl bromide or (4-pyridyl)methyl iodide.

8. The process as claimed in Claim 4, in which the carbonate ester (VI) is dimethyl carbonate, diethyl carbonate, dipropyl carbonate or methylethyl carbonate.

9. The process as claimed in Claim 1, in which the salt is that of hydrochloride, hydrobromide or hydroiodide; n being 2; and R^1 being methoxy, attached to 5- and 6- positions.

10. A quaternary ammonium salt (I) represented by the following formula;



(Wherein R^1 , n and X have the same meaning as defined in Claim 1.) .

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/JP 99/00111

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D213/50 C07D211/32

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 711 756 A (BAYER AG) 15 May 1996 cited in the application see claim 1	1-10
A	KLINGSBERG (EDITOR): "Pyridines and its derivatives Part two" , KLINGSBERG , NEW YORK XP002098667 see page 46	1,5,6
A	ABRAMOVITCH (EDITOR): "Pyridine and its derivatives, Supplement, part one" , JOHN WILEY & SONS XP002098668 see page 361	1,5,6
A	DE 28 00 919 A (UCB SA) 13 July 1978 see example 2	1,5,6
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

6 April 1999

Date of mailing of the international search report

16/04/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

De Jong, B

INTERNATIONAL SEARCH REPORT

International Application No

PCT/JP 99/00111

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>CHEMICAL ABSTRACTS, vol. 114, no. 21, 27 May 1991 Columbus, Ohio, US; abstract no. 207050, IRIUCHIJIMA, SHINOBU: "Preparation of 1-(acyloxybenzyl)piperidine hydrohalides" XP002098669 see abstract -& JP 03 011063 A (DENKI KAGAKU KOGYO K. K., JAPAN)</p> <p style="text-align: center;">-----</p>	1,5,6

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inter: International Application No

PCT/JP 99/00111

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0711756 A	15-05-1996	DE 4439822 A	29-08-1996
		AT 168676 T	15-08-1998
		CA 2162081 A	09-05-1996
		DE 59502882 D	27-08-1998
		ES 2121276 T	16-11-1998
		GR 3027698 T	30-11-1998
		JP 8225527 A	03-09-1996
		SI 711756 T	31-10-1998
		US 5606064 A	25-02-1997
DE 2800919 A	13-07-1978	GB 1542823 A	28-03-1979
		BE 862769 A	10-07-1978
		BG 28574 A	15-05-1980
		CA 1101426 A	19-05-1981
		CS 195652 B	29-02-1980
		DD 134089 A	07-02-1979
		DK 5778 A	12-07-1978
		FI 780028 A	12-07-1978
		FR 2376846 A	04-08-1978
		JP 1357480 C	13-01-1987
		JP 53087367 A	01-08-1978
		JP 61025031 B	13-06-1986
		LU 78839 A	18-09-1978
		NL 7800146 A	13-07-1978
		PT 67511 A,B	01-02-1978
		SE 7800184 A	12-07-1978
		SU 990761 A	23-01-1983
		ZA 7800158 A	25-10-1978